Caricamento...
Are we over-treating with checkpoint inhibitors?
Anti-PD-1 antibodies offer potentially life-saving treatment for some cancer patients, but their chronic administration generates high and ever-increasing costs. Despite licensing for long-term use, optimal treatment duration is unknown. We challenge the need for long-term treatment duration, using...
Salvato in:
| Pubblicato in: | Br J Cancer |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Nature Publishing Group UK
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6889152/ https://ncbi.nlm.nih.gov/pubmed/31527686 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0570-y |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|